Keynote 024 Orr. On june 17, 2019, the food and drug administration granted accelerated approval to pembrolizumab (keytruda, merck) for patients with metastatic small cell lung cancer. Consistent with results from keynote‐024 overall, first‐line pembrolizumab improved progression‐free survival and overall survival vs chemotherapy with.

In terms of efficacy, lisberg compared overall response rate (orr) data. Consistent with results from keynote‐024 overall, first‐line pembrolizumab improved progression‐free survival and overall survival vs chemotherapy with.